Source:http://linkedlifedata.com/resource/pubmed/id/10438735
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1999-9-7
|
| pubmed:abstractText |
We evaluated demographic characteristics and graft composition as risk factors for acute graft-versus-host disease (GVHD) in 160 adult recipients of HLA-identical allogeneic blood stem cell transplants. The patients received a median nucleated cell dose of 7.9 x 10(8)/kg and median C34(+) cell dose of 5.6 x 10(6)/kg. GVHD prophylaxis consisted of cyclosporine (CSA) and steroids, tacrolimus (FK506) and steroids, or FK506 and methotrexate. Grades 2 to 4 GVHD occurred in 31% (95% CI, 23% to 39%), and grades 3 to 4 GVHD in 14% (95% CI, 8% to 20%). In univariate analyses, GVHD prophylaxis with CSA and high CD34(+) cell doses were significant risk factors for grades 2 to 4 GVHD, but diagnosis, age, use of total body irradiation, donor sex, female donor for male recipient, donor parity, donor alloimmunization, viral serology, nucleated cell dose, CD3(+) cell dose, and CD56(+) cell dose did not alter the incidence of GVHD significantly. With a CD34(+) cell dose less than 8 x 10(6) CD34(+) cells/kg, the risk of grades 2 to 4 GVHD was significantly higher for those who received CSA (39%, 95% CI, 21% to 47%) in comparison with those on FK506 (18%, 95% CI, 10% to 26%) (P =.03), but GVHD prophylaxis regimen had less impact with a higher CD34(+) cell dose (overall grades 2 to 4 GVHD rate 52%, 95% CI, 37% to 67%). GVHD prophylaxis and CD34(+) cell dose are independent risk factors for acute GVHD after allogeneic blood stem cell transplantation.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:AnderliniPP,
pubmed-author:AnderssonB SBS,
pubmed-author:BraunschweigII,
pubmed-author:ChamplinRR,
pubmed-author:ClaxtonDD,
pubmed-author:ClearyKK,
pubmed-author:DonatiGG,
pubmed-author:FolloderJJ,
pubmed-author:GajewskiJJ,
pubmed-author:GiraltSS,
pubmed-author:HuhY OYO,
pubmed-author:KörblingMM,
pubmed-author:KhouriII,
pubmed-author:MehraRR,
pubmed-author:PrzepiorkaDD,
pubmed-author:SmithT LTL,
pubmed-author:UenoN TNT,
pubmed-author:van BesienKK
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
94
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1465-70
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:10438735-Adolescent,
pubmed-meshheading:10438735-Adult,
pubmed-meshheading:10438735-Aged,
pubmed-meshheading:10438735-Child,
pubmed-meshheading:10438735-Female,
pubmed-meshheading:10438735-Graft vs Host Disease,
pubmed-meshheading:10438735-HLA Antigens,
pubmed-meshheading:10438735-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10438735-Histocompatibility Testing,
pubmed-meshheading:10438735-Humans,
pubmed-meshheading:10438735-Immunosuppressive Agents,
pubmed-meshheading:10438735-Male,
pubmed-meshheading:10438735-Middle Aged,
pubmed-meshheading:10438735-Risk Factors,
pubmed-meshheading:10438735-Transplantation, Homologous
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.
|
| pubmed:affiliation |
Departments of Blood and Marrow Transplantation, Biomathematics, Laboratory Medicine and Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. donnap@bcm.tmc.edu
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|